nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2006-10-1-103-105nefr-479Research ArticleДИСКУССИЯ И ИНФОРМАЦИЯDISCUSSION AND INFORMATIONРЕНАЛЬНЫЙ КОНТИНУУМ: ВОЗМОЖНО ЛИ ОБРАТНОЕ РАЗВИТИЕ ХБП?RENAL CONTINUUM: IS CKD REVERSIBLE?ИвановД. Д.IvanovD. D.
кафедра нефрологии
Киевская медицинская академия последипломного образования им. П.Л. ШупикаUkraine200610012006101103105Copyright © Иванов Д.Д., 20062006Иванов Д.Д.Ivanov D.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/479
.
.
ренальный континуумхроническое заболевание почек (ХЗП)хроническая болезнь почек (ХБП)хроническая почечная недостаточность (ХПН)ренопротекцияrenal continuumchronic kidney illnesschronic kidney diseasechronic renal failureregression of CKDrenoprotectionReferencesAnonymous. Part 1. Executive summary. Am J Kidney Dis 2002; 39 [Suppl. 1]: S17-S31Anonymous. Part 1. Executive summary. Am J Kidney Dis 2002; 39 [Suppl. 1]: S17-S31Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17Hogg RJ, Furth S, Lemeley KV et al. Pediatrics 2003; 111 (6): 1416-1421Hogg RJ, Furth S, Lemeley KV et al. Pediatrics 2003; 111 (6): 1416-1421Смирнов АВ, Каюков ИГ, Есаян АМ и др. Превентивный подход в современной нефрологии. Нефрология 2004; 8(3): 7-14Смирнов АВ, Каюков ИГ, Есаян АМ и др. Превентивный подход в современной нефрологии. Нефрология 2004; 8(3): 7-14Johnson CA et al. Clinical practice guidelines for chronic kidney disease in adults: Part I. Am Pham PhysicianSept.1, 2004; 70(5): 869-876Johnson CA et al. Clinical practice guidelines for chronic kidney disease in adults: Part I. Am Pham PhysicianSept.1, 2004; 70(5): 869-876Johnson CA et al. Clinical practice guidelines for chronic kidney disease in adults: Part II. Am Pham Physician 2004; 70(6): 1091-1097Johnson CA et al. Clinical practice guidelines for chronic kidney disease in adults: Part II. Am Pham Physician 2004; 70(6): 1091-1097Somermeyer M. The disease-management approach to chronic kidney disease: A nephrologist’s perspective. Dial & Transplant 2005; 34 (11): 820-825Somermeyer M. The disease-management approach to chronic kidney disease: A nephrologist’s perspective. Dial & Transplant 2005; 34 (11): 820-825Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7-15Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58(1): 353-362Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58(1): 353-362Іванов ДД. Модифікація факторів ризику ХХН. Мистецтво лікування 2005; 8: 66-71Іванов ДД. Модифікація факторів ризику ХХН. Мистецтво лікування 2005; 8: 66-71Иванов ДД. Выбор фармакотерапии при ХБП. Medicus Amicus 2005; 5: 28-29Иванов ДД. Выбор фармакотерапии при ХБП. Medicus Amicus 2005; 5: 28-292nd Middle East & Africa Dialysis Forum: Conference Report. Dial & Transplant 2005; 34 (12): 883-8962nd Middle East & Africa Dialysis Forum: Conference Report. Dial & Transplant 2005; 34 (12): 883-896Broe MED. Tubular regeneration and the role of bone marrow cells: «stem cell therapy» – a panacea? Nephrol Dial Transplant 2005; 20 (11): 2318-2320Broe MED. Tubular regeneration and the role of bone marrow cells: «stem cell therapy» – a panacea? Nephrol Dial Transplant 2005; 20 (11): 2318-2320Follow us. The Official ERAEDTA Newsletter. Year 1, Issue 3: 1-3Follow us. The Official ERAEDTA Newsletter. Year 1, Issue 3: 1-3Wolf G. Zenon’s paradox or how much to lower blood pressure for optimal renoprotection. Nephrol Dial Transplant 2005; 20 (11): 2304-2307Wolf G. Zenon’s paradox or how much to lower blood pressure for optimal renoprotection. Nephrol Dial Transplant 2005; 20 (11): 2304-2307Ivanov DD, Kushnirenko SV. Selective COX-2 inhibitor increase BRA II 1 +ACEI antiproteinuric effect in patients with metabolic syndrome. ERA-EDTA Congress, 2004. Abstract book: MP 134, P.274Ivanov DD, Kushnirenko SV. Selective COX-2 inhibitor increase BRA II 1 +ACEI antiproteinuric effect in patients with metabolic syndrome. ERA-EDTA Congress, 2004. Abstract book: MP 134, P.274Ivanov DD, Kushnirenko SV. BRA II 1 +ACEI vs BRA II 1 +ACEI+COX-2 inhibitor vs BRA II 1 +ACEI+Monoxidin in patients with diabetic nephropathy (DN). ERA-EDTA Congress, 2004. Abstract book: MP 119Ivanov DD, Kushnirenko SV. BRA II 1 +ACEI vs BRA II 1 +ACEI+COX-2 inhibitor vs BRA II 1 +ACEI+Monoxidin in patients with diabetic nephropathy (DN). ERA-EDTA Congress, 2004. Abstract book: MP 119Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J 2004; 25: 1454-1470Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. Eur Heart J 2004; 25: 1454-1470FPIN’s Clinical Inquiries. Do ACE Inhibitors Decrease Mortality in Patients with Hypertension? Am Fam Phys 2004: 153-154FPIN’s Clinical Inquiries. Do ACE Inhibitors Decrease Mortality in Patients with Hypertension? Am Fam Phys 2004: 153-154Karlamangla AS. Increases in serum non-high-density lipoprotein cholesterol may be beneficial in some high-functional older adults: MacArthur Studies of Successful Aging. J Am Geriartr Soc 2004; 52:487-94Karlamangla AS. Increases in serum non-high-density lipoprotein cholesterol may be beneficial in some high-functional older adults: MacArthur Studies of Successful Aging. J Am Geriartr Soc 2004; 52:487-94Sharma AM, Hollander A, Koster J. Telmisartan in patients with mild/moderate hypertension and chronic renal disease (ESPIRIT study group). Clinical Nephrology 2005; 63 (4): 250-257Sharma AM, Hollander A, Koster J. Telmisartan in patients with mild/moderate hypertension and chronic renal disease (ESPIRIT study group). Clinical Nephrology 2005; 63 (4): 250-257Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptors blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 2005; 67: 799-812Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptors blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 2005; 67: 799-812Wu SC, Liu SP, Chiang HT, Lin SL. Prospective end randomized study of the antihypertensive effect and tolerability of three antihypertensive agents losartan, amlodipine and lisinopril in hypertensive patient. Heart Vessels 2004; 19 (1): 13-18.Wu SC, Liu SP, Chiang HT, Lin SL. Prospective end randomized study of the antihypertensive effect and tolerability of three antihypertensive agents losartan, amlodipine and lisinopril in hypertensive patient. Heart Vessels 2004; 19 (1): 13-18.www.nephrology.kiev.ua (Перший Український нефрологічний сайт)www.nephrology.kiev.ua (Перший Український нефрологічний сайт)
The authors declare that there are no conflicts of interest present.